56,040 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by Generali Asset Management SPA SGR

Generali Asset Management SPA SGR purchased a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 56,040 shares of the medical equipment provider's stock, valued at approximately $4,040,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HOLX. General Partner Inc. bought a new position in Hologic in the 4th quarter worth $26,000. Groupama Asset Managment lifted its holdings in Hologic by 9.9% in the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after acquiring an additional 261 shares during the last quarter. First Horizon Advisors Inc. boosted its holdings in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after purchasing an additional 134 shares during the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock worth $42,000 after purchasing an additional 260 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several research firms have weighed in on HOLX. Morgan Stanley cut their price target on Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Stephens restated an "overweight" rating and issued a $84.00 price target on shares of Hologic in a research report on Thursday, February 6th. Leerink Partnrs lowered shares of Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Needham & Company LLC cut shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. Finally, Royal Bank of Canada lowered their price target on shares of Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $84.62.

Hologic Trading Up 0.8 %

Shares of NASDAQ HOLX traded up $0.46 during mid-day trading on Friday, reaching $61.47. The company had a trading volume of 7,416,503 shares, compared to its average volume of 1,750,784. Hologic, Inc. has a 52 week low of $60.34 and a 52 week high of $84.67. The business's 50-day moving average is $66.06 and its 200-day moving average is $73.99. The stock has a market cap of $13.79 billion, a price-to-earnings ratio of 19.39, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.